Modality
siRNA
MOA
PCSK9i
Target
MDM2
Pathway
Wnt
MG
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
Jul 2020
→ May 2030
Phase 1Current
NCT05714419
1,678 pts·MG
2020-07→2030-05·Completed
1,678 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-044.1y awayInterim· MG
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Complet…
Catalysts
Interim
2030-05-04 · 4.1y away
MG
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05714419 | Phase 1 | MG | Completed | 1678 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |